This content is for informational purposes only and is not a substitute for professional advice.
Saffron has mood-adjacent human research, which is exactly why the trial needs stronger guardrails. Use interaction checks before testing, especially with antidepressants, bipolar disorder, pregnancy, or suicidal thoughts.
Eligibility criteria
This is not a depression-treatment guide. If symptoms are moderate, severe, worsening, or paired with self-harm thoughts, clinician care is the next step.
| Screen | Requirement |
|---|---|
| Medication | Review SSRIs, SNRIs, MAOIs, stimulants, sedatives |
| Diagnosis | Extra caution with bipolar disorder or psychosis history |
| Product | Standardized saffron extract with clear dose |
| Outcome | Mood score, irritability, sleep, and function |
| Stop | Agitation, mood elevation, insomnia, worsening mood |
Protocol
Run two weeks of baseline mood and sleep tracking. Choose one validated mood questionnaire or a consistent daily score, plus a function marker such as work completion or social avoidance. Add saffron only after the baseline is stable enough to interpret.
Do not combine saffron with a new therapy change, medication change, stimulant change, or sleep supplement. If mood improves, keep logging for another two weeks before deciding.
Decision table
| Result | Action |
|---|---|
| Mood and function improve, sleep stable | Continue short-term with review |
| Mood improves, sleep worsens | Stop or seek review |
| Agitation or elevated mood | Stop and seek care |
| No change after review window | Discontinue |
Disclosure
Unfair does not sell saffron. In Unfair, saffron should be tagged as mood support with visible stop conditions and not treated as a replacement for care.